I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on 2-5-04

TOWNSEND and TOWNSEND and CREW LLP

By: Jonda Shaffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jonathan A. Ellman et al.

Application No.:

Filed: February 5, 2004

For: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS USING ASPATYL PROTEASE

INHIBITORS

Examiner:

Art Unit:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Attorney Docket No.: 18062G-002020

Client Reference No.: 99-361-5

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/534,706, filed March 24, 2000 (Attorney Docket No. 18062G-002010). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Jonathan A. Ellman *et al.* Application No.: Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Eugenia Garrett Wackowsk Reg No. 37,330

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 925-472-5000 Fax: 925-472-8895

EGW:lls 60134548 v1

١

Substitu	te for form 1449A/PT	го			Complete if Known
				Application Number	
INFO	DRMATION	I DI	SCLOSURE	Filing Date	February 5, 2004
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Ellman, Jonathan A.
				Art Unit	
	(use as many sh	eets a	s necessary)	Examiner Name	
Sheet	1	of	5	Attorney Docket Number	18062G-002020

			U.S. PATENT DO	CUMENTS+	
		Document Number			
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,492,812	02/20/1996	Vooheis	
	2	US-5,872,101	02/16/91999	Munoz et al.	
		US-			
•		US-			
		US-			
		US-			
•		US-			
	1	US-			
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For	eign Patent Doo Number ⁴	cument Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
	3	PC	WO 98/337	95	08/06/1998			. 🗆	
		•							

Examiner Signature	Date Con	nsidered	

Substitute	for form 1449B/PT(o		Complete if Known			
		D 10	OL COURT	Application Number			
			CLOSURE	Filing Date	February 5, 2004		
STAT	STATEMENT BY APPLICANT			First Named Inventor	Ellman, Jonathan A.		
				Art Unit			
(t	(use as many sheets as necessary)			Examiner Name			
Sheet	2	of	5	Attorney Docket Number	18062G-002020		

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
	4	AGARWAL et al., J. Med. Chem., 29:2519-2524 (1986)	
	5	AUGELLI-SZAFRAN et al., Ann. Reports Med. Chem., 34:21-30 (1999)	
-	6	AUSTEN et al., Biomed. Pept. Proteins Nucleic Acids, 1:243-246 (1995)	
	7	BAHR et al., Experimental Neurology, 129:81-94 (1994)	
	8	BALDWIN et al., Proc. Natl. Acad. Sci. USA, 90:6796-6800 (1993)	
	9	BEDNARSKI et al., J. Neurochem., 67(5):1845-1855 (1996)	
-	10	BEDNARSKI et al., J. Neurosci., 17(11):4006-4021 (1997)	
	11	BEDNARSKI et al., NeuroReport, 9:2089-2094 (1998)	
	12	BI et al., Exp. Neurol., 158:312-327 (1999)	
	13	BI et al., J. Comp. Neuro., 401:382-394 (1998)	
	14	BRAAK et al., Acta Neuropathol., 46:79-83 (1979)	
	15	CATALDO et al., Journal of Neuropathology and Experimental Neurology, 55(6):704-715 (1996)	
	16	CATALDO et al., Proc. Natl. Acad. Sci. USA, 87:3861-3865 (1990)	
	17	CATALDO et al., Medical Sciences, 88:10998-11002 (1991)	
	18	CATALDO et al., Brain Research, 513:181-192 (1990)	
	19	CHEVALLIER et al., Brain Res., 750:11-19 (1997)	

		T
Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449B/PT	0		Complete if Known				
INITO!	NFORMATION DISCLOSUR STATEMENT BY APPLICAN (use as many sheets as necessary)			Application Number				
		_		Filing Date	February 5, 2004			
STAT	STATEMENT BY APPLICANT			First Named Inventor	Ellman, Jonathan A.			
				Art Unit				
(1	ise as many sh	eets as	s necessary)	Examiner Name				
Sheet	3	of	5	Attorney Docket Number	18062G-002020			

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	lo.1 publisher, city and/or country where published.					
	20	CRAWFORD et al., Neurosci. Lett., 289(1):61-65 (2000), Medline Abstract 10899409					
	21	DREYER et al., Eur. J. Biochem., 224:265-271 (1994)					
	22	ESTUS et al., Ann. N.Y. Acad. Sci., 674:138-148 (1992)					
	23	GOODE et al., J. Cell Biol., 124:769-782 (1994)					
	24	HAQUE et al., J. Med. Chem., 42:1428-1440 (1999)					
	25	HAWLEY et al., "The Condensed Chemical Dictionary," 1977, Van Nostrand, New York, page 822					
	26	HOFFMAN et al., Neuroscience Letters, 250:75-78 (1998)					
	27	II et al., Virchows Archiv A Pathol Anat, 423:185-194 (1993)					
	28	ISAHARA et al., Neuroscience, 91(1):233-249 (1999)					
	29	JUPP et al., Biochem. J., 265:871-878 (1990)					
	30	KENESSEY et al., J. Neurochem., 69(5):2026-2038 (1997)					
	31	KICK et al., Chemistry & Biology, 4(4):297-307 (1997)					
	32	KICK et al., J. Med. Chem., 38:1427-1430 (1995)					
	33	KOSIK et al., Proc. Natl. Acad. Sci. USA, 83:4044-4088 (1986)					
	34	KOWALL et al., Proc. Natl. Acad. Sci. USA, 88:7247-7251 (1991)					
<u></u>	35	KRAFFT et al., Methods Enzymol., 241:70-86 (1994)					

		·
Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449B/PT	·o		Complete if Known			
INIEG		DIO	OL OOUDE	Application Number			
	=	_	CLOSURE	Filing Date	February 5, 2004		
STAT	EMENT B	SY A	PPLICANT	First Named Inventor	Ellman, Jonathan A.		
				Art Unit	1.0		
(4	(use as many sheets as necessary)			Examiner Name			
Sheet	4	of	5	Attorney Docket Number	18062G-002020		

	-	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T
Examiner Initials *	Cite No. ¹	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	36	KREUTZBERG, ArzneimForsch./Drug Res. 45(I), Nr. 3a, 357-360 (1995)	
	37	LAMB et al., Nature Genet., 5:22-29 (1993)	
	38	LEE et al., J. Am. Chem. Soc., 120:9735-9747 (1998)	
	39	LEE et al., Science, 251:675-678 (1991)	
	40	LEVY-STRUMPF et al., Oncogene, 17:3331-3340 (1998)	
	41	LINDWALL et al., J. Biol. Chem., 259(19):12241-12245 (1984)	
	42	MACKAY et al., Eur. J. Biochem., 244:414-425 (1997)	
	43	MANN et al., Neuropathol. Appl. Neurobiol., 13:123-139 (1987)	
	44	MATEO et al., Am. J. Med. Genet., 114(1):31-33 (2002), Medline Abstract PMID 11840502	
	45	MATSUI et al., Ann. Neurol., 49(4):544-545 (2001), Medline Abstract PMID 11310638	
	46	MATSUO et al., Neuron, 13:989-1002 (1994)	
	47	MENZER et al., Am. J. Med. Genet., 105(2):179-182 (2001), Medline Abstract PMID 11304834	
	48	MULLAN et al., Nature Genet., 1:345-347 (1992)	
	49	MURPHY et al., J. Biol. Chem., 274(17):11914-11923 (1999)	
	50	NAKAMURA et al., Neurosci. Lett., 97:215-220 (1989)	
	51	NAKANISHI et al., Exp. Neurol., 126:119-128 (1994)	

			-	
Examiner	-	Date		
Signature		Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known			
INIEO		DIC	CL OCUDE	Application Number	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			-	Filing Date	February 5, 2004
			PPLICANT	First Named Inventor	Ellman, Jonathan A.
				Art Unit	
(L	ise as many she	ets as	necessary)	Examiner Name	
Sheet	5	of	5	Attorney Docket Number	18062G-002020

·		NON PATENT LITERATURE DOCUMENTS	Ţ
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	52	NAKANISHI et al., J. Neurochem., 68:739749 (1997)	
	53	NIETO et al., J. Neurosci., 37(1):163-170 (1990)	
	54	OHSAWA et al., Arch. Histol. Cytol., 61(5):395-403 (1998)	
	55	OLSON et al., "Annual Reports Med. Chem.," 35:31-40 (2000)	
	56	PEARSON et al., Proc. Natl. Acad. Sci. USA, 90:10578-10582 (1993)	
7=	57	PURPURA et al., Brain Res., 116:1-21 (1976)	
	58	ROBERG et al., Am. J. Pathol., 152(5):1151-1156 (1988)	
******	59	SELKOE, TINS, 16(10):403-409 (1993)	
	60	WAGNER et al., J. Clinical Invest., 104:1329-1332 (1999)	
	61	WEINGARTEN et al., Proc. Natl. Acad. Sci. USA, 72(5):1858-1862 (1975)	
	62	WILEY et al., Med. Res. Rev., 13(3):327-384 (1993)	
	63	WILLIAMS, Jr. et al., Biochemistry, 18:2499-2503 (1979)	
	64	WISCHIK et al., Proc. Natl. Acad. Sci. USA, 85:4506-4510 (1988)	
	65	YONG et al., Exp. Neurol., 157:150-160 (1999)	
_	66	"Webster's New World Dictionary, College Ed.," no author listed, World Publishing, p. 946 (1962)	
	67	"Developments in the Treatment of Parkinson's Disease," <i>Drug and Ther. Bull., 35</i> :36-40 (1997)	

Examiner Signature	Date Considered	
Signature	Colloidered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.